Tests show that pregabalin is effective in treating fibromyalgia

Business Club July 15th Pfizer (Japan) announced the preliminary results of Lydia's research on A0081208. The study was a 16-week, randomized, double-blind, multi-center, placebo-controlled study designed to evaluate the safety and effectiveness of pregabalin in the treatment of fibromyalgia. The preliminary results showed that the average pain score of the pregabalin group was significantly lower than that of the placebo.

The main features of fibromyalgia are extensive chronic musculoskeletal pain and tenderness. The pathophysiology of fibromyalgia is relatively complex, and the current understanding of it is not yet thorough, but fibromyalgia is a disabling disease that seriously affects the quality of life of patients.

Akihisa Harada, vice president of development at Pfizer (Japan), said that he was pleased with the preliminary results of the study and looked forward to a better understanding of the potential benefits Lyrica might have for patients with fibromyalgia in Japan.

The A0081208 study compared pregabalin with a flexible dose (300-450 mg/day twice daily) versus placebo in patients with fibromyalgia. The study included 501 patients in 45 research centers in Japan (251 in the pregabalin group and 250 in the placebo group). The most common side effects seen in this study included drowsiness, dizziness, weight gain, constipation, paresthesia, peripheral edema, and blurred vision.